BACKGROUND: Methamphetamine (MA) use disorders are pervasive global social problems that produce large medical and public health burdens. Abnormalities in pituitary hormonal regulation have been observed in preclinical models of substance abuse and in human substance abusers. They have, however, not been studied before in MA-dependent human subjects. OBJECTIVES: To determine if MA-dependent research volunteers differ from healthy control subjects in plasma levels of adrenocorticotropic hormone (ACTH), cortisol, or prolactin, or in pituitary dopamine D(2) receptor availability during early abstinence from MA. METHODS: MA-dependent subjects (N = 31), who were not seeking treatment, resided on an inpatient ward for up to 5 weeks. Abstinence was confirmed by daily urine drug screening. Venous blood was sampled for plasma hormone levels, and positron emission tomography with [(18)F]fallypride was performed to determine dopamine D(2) receptor availability during the first week of abstinence. Venous blood was sampled again for hormone levels during the fourth week of abstinence. Matched healthy volunteers (N = 23) participated as a comparison group. RESULTS: MA-dependent and healthy comparison subjects did not differ in plasma ACTH or cortisol levels, but had an elevated plasma prolactin at both the first week and fourth week of abstinence. There was no group difference in pituitary dopamine D(2) receptor availability. CONCLUSION: MA-dependent individuals have abnormalities in prolactin regulation, which is not likely due to alterations in pituitary dopamine D(2) receptor availability. SCIENTIFIC SIGNIFICANCE: MA dependence is associated with elevated prolactin levels, which may contribute to medical comorbidity in afflicted individuals.
BACKGROUND:Methamphetamine (MA) use disorders are pervasive global social problems that produce large medical and public health burdens. Abnormalities in pituitary hormonal regulation have been observed in preclinical models of substance abuse and in human substance abusers. They have, however, not been studied before in MA-dependent human subjects. OBJECTIVES: To determine if MA-dependent research volunteers differ from healthy control subjects in plasma levels of adrenocorticotropic hormone (ACTH), cortisol, or prolactin, or in pituitary dopamine D(2) receptor availability during early abstinence from MA. METHODS: MA-dependent subjects (N = 31), who were not seeking treatment, resided on an inpatient ward for up to 5 weeks. Abstinence was confirmed by daily urine drug screening. Venous blood was sampled for plasma hormone levels, and positron emission tomography with [(18)F]fallypride was performed to determine dopamine D(2) receptor availability during the first week of abstinence. Venous blood was sampled again for hormone levels during the fourth week of abstinence. Matched healthy volunteers (N = 23) participated as a comparison group. RESULTS: MA-dependent and healthy comparison subjects did not differ in plasma ACTH or cortisol levels, but had an elevated plasma prolactin at both the first week and fourth week of abstinence. There was no group difference in pituitary dopamine D(2) receptor availability. CONCLUSION: MA-dependent individuals have abnormalities in prolactin regulation, which is not likely due to alterations in pituitary dopamine D(2) receptor availability. SCIENTIFIC SIGNIFICANCE: MA dependence is associated with elevated prolactin levels, which may contribute to medical comorbidity in afflicted individuals.
Authors: Su-xia Li; Jing Li; David H Epstein; Xiang Yang Zhang; Thomas R Kosten; Lin Lu Journal: Am J Drug Alcohol Abuse Date: 2008 Impact factor: 3.829
Authors: E Gouzoulis-Mayfrank; B Thelen; E Habermeyer; H J Kunert; K A Kovar; H Lindenblatt; L Hermle; M Spitzer; H Sass Journal: Psychopharmacology (Berl) Date: 1999-02 Impact factor: 4.530
Authors: Leonardo Vieira Neto; Evelyn de O Machado; Raul M Luque; Giselle F Taboada; Jorge B Marcondes; Leila M C Chimelli; Leonardo Pereira Quintella; Paulo Niemeyer; Denise P de Carvalho; Rhonda D Kineman; Mônica R Gadelha Journal: J Clin Endocrinol Metab Date: 2009-03-17 Impact factor: 5.958
Authors: Buyean Lee; Edythe D London; Russell A Poldrack; Judah Farahi; Angelo Nacca; John R Monterosso; Jeanette A Mumford; Andrew V Bokarius; Magnus Dahlbom; Jogeshwar Mukherjee; Robert M Bilder; Arthur L Brody; Mark A Mandelkern Journal: J Neurosci Date: 2009-11-25 Impact factor: 6.167